CJC-1295 is a modified analog of growth hormone-releasing hormone (GHRH), and the “No DAC” designation tells you something important about how researchers are using it. The DAC (Drug Affinity Complex) version binds to albumin to extend its half-life dramatically. The No DAC version doesn’t, which means it produces a more physiological, pulsatile pattern of growth hormone release.
That distinction matters in research. Natural GH secretion is pulsatile, not continuous. If you’re studying the effects of GH stimulation, the pattern of that stimulation affects the biology. CJC-1295 No DAC is the version that preserves that pulsatile quality.
Key Takeaways
- CJC-1295 is a synthetic 29-amino acid GHRH analog designed to stimulate pituitary GH release
- The “No DAC” version produces pulsatile GH release patterns that mimic natural physiology
- Stimulates both GH and IGF-1 secretion in published human and animal studies
- Two landmark studies published in 2006 documented prolonged GH stimulation with a clean safety profile
- Often studied alongside Ipamorelin for complementary GH stimulation through different receptor pathways
- Distinct from the DAC version, which has extended half-life through albumin binding
What Is CJC-1295 No DAC?
The full name is Modified Growth Hormone Releasing Hormone (1-29) without Drug Affinity Complex. It’s a synthetic 29-amino acid peptide that acts as an analog of the naturally occurring growth hormone-releasing hormone.
GHRH is produced in the hypothalamus and travels to the pituitary gland, where it triggers the synthesis and release of growth hormone. CJC-1295 mimics this signal at the pituitary level. The modifications to the natural GHRH sequence were made to improve stability and extend the effective window compared to native GHRH, which degrades quickly.
The DAC versus No DAC distinction gets asked about constantly in research circles. The DAC version adds a molecule that allows the peptide to bind to albumin in the bloodstream, extending its half-life from minutes to days. This creates continuous GH stimulation rather than pulsatile. The No DAC version has a shorter active window, producing GH spikes that look more like what the pituitary does naturally.
If you’re sourcing research-grade CJC-1295 No DAC, make sure the product is specifically labeled as the No DAC variant. The two compounds have different research applications and shouldn’t be used interchangeably in protocols.
How Does CJC-1295 No DAC Work?
GHRH Receptor Agonism
CJC-1295 binds to GHRH receptors on pituitary somatotroph cells, the cells responsible for producing and releasing growth hormone. When the GHRH receptor is activated, it triggers a cAMP signaling cascade inside the cell that results in both GH synthesis and release.
The key word is “pulsatile.” The pituitary naturally releases GH in discrete pulses rather than continuously. CJC-1295 No DAC’s shorter active window means each administration produces a GH pulse rather than sustained elevation, which more closely mirrors natural physiology.
IGF-1 Stimulation
Downstream of GH release, the liver produces insulin-like growth factor 1 (IGF-1) in response to elevated GH levels. Studies on CJC-1295 have documented elevation of both GH and IGF-1, which is the expected cascade. Researchers studying body composition effects of GH secretagogues typically measure both markers.
Preserving Feedback Mechanisms
One of the arguments for studying GHRH analogs like CJC-1295 rather than direct GH administration is that the natural feedback mechanisms remain intact. The pituitary still responds to somatostatin (the inhibiting hormone) and the hypothalamus still regulates the overall pulse pattern. The compound stimulates the system rather than overriding it.
What Does the Research Show?
2006 Study: Prolonged Stimulation of GH and IGF-1
The foundational CJC-1295 study was published in 2006 with PubMed ID 16352683. The research documented prolonged stimulation of growth hormone and IGF-1 secretion in healthy adults. Notably, it described an acceptable safety profile at the doses studied, with no serious adverse events.
This was a significant paper because it established that a GHRH analog could produce meaningful, measurable GH responses in human subjects with a clean tolerability profile.
2006 Study: Pulsatile Secretion Preserved
A second study from the same year (PMID 17018654) examined the quality of GH secretion during CJC-1295 administration. The key finding: pulsatile secretion of GH persists during continuous stimulation by CJC-1295. Researchers documented GH and IGF-1 stimulation across multiple animal species and in normal human subjects, along with enhanced growth in rats.
The preservation of pulsatility was the headline finding. It addressed a concern that long-acting GHRH analogs might produce tonic stimulation that desensitizes the pituitary over time. The data suggested the natural rhythm was maintained.
Animal Model Research
Multiple rodent studies have explored CJC-1295’s effects on body composition, bone density, and metabolic parameters. These studies provide mechanistic context for the human data and have explored longer-term administration patterns that wouldn’t be appropriate in early human trials.
Growth effects in young animals and metabolic effects in older animals have both been documented, pointing toward different research applications depending on the model being used.
Purity, Testing, and Quality Considerations
CJC-1295 is a 29-amino acid peptide, placing it in the moderate complexity range for synthesis. Standard purity thresholds apply: 98%+ by HPLC, with mass spectrometry confirmation of molecular weight. The specific modification patterns that distinguish CJC-1295 from raw GHRH(1-29) should be verifiable through molecular weight analysis.
COA documentation should come from an independent third-party lab. The peptide market for GHRH analogs has quality variation, and manufacturer self-reporting isn’t a sufficient standard for research-grade material.
Third-party tested CJC-1295 No DAC from Concordia Research Chems includes documented purity analysis and sequence verification. Consistency across research batches is important when comparing results over time.
Related Compounds
CJC-1295 No DAC is part of a well-studied group of growth hormone secretagogues that researchers often study together.
Ipamorelin is the most common study partner for CJC-1295. The two compounds work through different receptor pathways, CJC-1295 through the GHRH receptor and Ipamorelin through the ghrelin/GHS receptor, which means they stimulate GH release through complementary mechanisms. Researchers study them together specifically because of this receptor diversity. Full breakdown in the Ipamorelin research guide.
Sermorelin is another GHRH analog, specifically GHRH(1-29) without CJC-1295’s modifications for improved stability. The pharmacokinetic profiles are different, with sermorelin having a shorter effective window and CJC-1295 having a more extended one. See the Sermorelin guide.
Tesamorelin is a 44-amino acid GHRH analog that achieved FDA approval for a specific indication. It shares the GHRH receptor pathway with CJC-1295 but has a different development and regulatory history. The Tesamorelin guide covers the comparison.
Where the Research Is Heading
CJC-1295 No DAC occupies a specific niche in GH secretagogue research because of the pulsatile release profile. As researchers become more sophisticated about how GH pulse patterns affect downstream biology, compounds that preserve physiological pulsatility become increasingly relevant.
The combination studies with Ipamorelin represent an interesting research direction, since the dual-pathway approach to GH stimulation opens questions about whether complementary receptor activation produces different biological effects than single-pathway stimulation.
Concordia Research Chems carries research-grade CJC-1295 No DAC for laboratory research. If you’re designing research comparing GHRH analogs with different pharmacokinetic profiles, having verified, consistently sourced compounds is essential for meaningful data.
Not sure which compound fits your research goals?
Take our 60-second quiz →Get a personalized recommendation based on what you're studying.